Business Wire

New Access Signs Extended Deal with Catella Bank for Its Entire Front-Office Solution Suite

17.7.2017 11:51 | Business Wire

Jaa

New Access, leading provider of Front-to-Back-office software solution dedicated to the private banking and wealth management industries, has signed its first post-acquisition deal with Catella Bank. Catella Bank is an Apsys client expanding to New Access’ entire Front-Office solution suite: Banker’s Front. The suite includes Equalizer III New Access’ portfolio management system together with the e-Banking platform. Catella Bank will also be using New Access’ Client Data Management solution: CIM.

Catella Bank has chosen to trust New Access for its ability to provide a comprehensive Front-to-Back solution compliant with MiFID II regulations and requirements, as well as the new IFRS 9 accounting rules.

“It is an important milestone for us and a valuable differentiator to have a unique provider covering our Front-to-Back needs. New Access’ Front-Office suite will support our digitalization approach towards our clients helping our relationship managers to interact with them conveniently anytime, anywhere,” says Michael Pickett, COO & Head of IT at Catella Bank.

“Catella Bank has been using our core banking solution Apsys for many years. They now have decided to expand our partnership by adding client data management and our entire Front-Office solution suite. This will allow the bank to achieve regulatory compliance and its digital transformation while this partnership marks the beginning of a new chapter for New Access positioning itself as a comprehensive Front-to-Back banking solutions provider,” explains Vitus Rotzer, Managing Director at New Access.

The entire solution will be deployed in Catella Bank for both Luxembourg and Sweden entities. It will be New Access’ first installation in Sweden.

About New Access
New Access provides agile and scalable front-to-back office software solutions dedicated to the private banking and wealth management industries. New Access software solutions are designed to meet the specific requirements of the private banking and wealth management industries evolving in a complex and changing regulatory environment helping bankers to connect conveniently and efficiently with their clients thanks to new digital channels. Our offer covers the full client relationship lifecycle from account opening, through client data and document management to the management of his portfolios including: Portfolio and Order Management (PMS/OMS) with Equalizer III, e-Banking, On boarding and Client Relationship Management (CRM) with Branch, secure Electronic Document Management (EDMS) with Logical Access, client data management with CIM and a comprehensive core banking solution with Apsys.
With headquarters in Switzerland, New Access already installed its solutions in over 180 sites in 20 countries.

About Catella Bank
Catella Bank is a full-service bank offering a complete range of payment, corporate banking and wealth management services to private and corporate clients. A leading European bank within its areas of expertise for 25 years taking pride in working closely with its clients to create tailored solutions to meet their needs.
Catella Bank is registered in Luxembourg and is part of the Catella Group, listed on Nasdaq Stockholm.

www.newaccess.ch

Contact information

New Access
Aurélie Totin, +41-22-879-99-11
aurelie.totin@newaccess.ch

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Major Terrorist Plot Foiled in Saudi Arabia, Ministry of Interior Announces21.7.2017 21:33Tiedote

The following is a statement from Saudi Arabia’s Ministry of Culture and Information: This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005575/en/ Weapons and other items found in the possession of the three terrorists are an indication of the ugliness and severity of the acts of terrorism they were planning to carry out, victimizing innocent lives and private and public property. (Photo: ME NewsWire) The Saudi Ministry of Interior has announced that a major terrorist attack was prevented by security services in the city of Saihat in the Qatif governorate. On the evening of Friday, July 14th, security services intercepted a stolen Toyota Corolla vehicle in a busy, built-up district of the city. As the stolen vehicle was surrounded by security services, three men in the ca

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV21.7.2017 15:09Tiedote

Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for SYMTUZA™ (darunavir/cobicistat/emtricitabine/tenofovir alafenamide [D/C/F/TAF]), a once-daily darunavir-based single tablet regimen (STR). If approved, it will be the only darunavir-based STR indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents aged 12 years and older with body weight of at least 40 kg, with genotypic testing guiding use. This STR combines the proven efficacy and durability of darunavir with the improved renal laboratory and bone mineral density profile of F/TAF as compared to F/TDF (tenofovir disoproxil fumarate), and will be the only treatment that could deliver the adherence advantag

Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (Telotristat Ethyl), for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy21.7.2017 14:26Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion recommending the approval of Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. The CHMP positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for use in the 28 countries of the European Union, as well as Norway, Liechtenstein and Iceland. David Meek, Chief Executive Officer of Ipsen, said: “The positive CHMP opinion for Xermelo ® is an important milestone towards providing innovative s

NRI Secure Launches Japan's First "Blockchain Assessment" Service21.7.2017 10:00Tiedote

NRI SecureTechnologies, Ltd. (President: Jun Odashima; hereinafter NRI Secure), a leading provider of information security solutions in Japan, has begun providing Japan’s first-ever*1 “Blockchain Assessment,” a security Assessment service designed for systems and services which use blockchain technology*2. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170721005012/en/ Overview of the "Blockchain Assessment" Service (Graphic: Business Wire) As the blockchain technology has become more widespread, the presence of security-related vulnerabilities has also become increasingly apparent. In particular, with regard to smart contracts, *3 one of a constituent element of services using the blockchain, a cyberattack carried out on any vulnerable programs could lead to major threats or eve

Business Figures for the First Half of 2017: Sartorius Continues to Grow21.7.2017 08:00Tiedote

Sartorius (FWB:SRT), a leading international laboratory and pharmaceutical equipment supplier, continues on the growth track. In the first half of 2017, solid organic business development and two acquisitions led to a significant increase in sales revenue and earnings1. "Sartorius has continued its dynamic, profitable development," said CEO and Executive Board Chairman Dr. Joachim Kreuzburg in commenting on the company's first-half performance. "Both divisions achieved solid organic growth in an environment that was especially challenging in North America, and have made quick progress in integrating the businesses most recently acquired. In the Lab Products & Services Division, the bioanalytics unit newly created by our acquisitions has already contributed significant revenues and earnings. We see further considerable growth potential ahead for this business just as for the

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme